Home » Shire’s ADHD Drug Succeeds in Trial to Treat Binge Eating

Shire’s ADHD Drug Succeeds in Trial to Treat Binge Eating

November 6, 2013

Shire has announced that its ADHD amphetamine drug Vyvanse has passed a trial evaluating its effectiveness in treating binge eating disorder.
Reuters

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Shire’s ADHD Drug Succeeds in Trial to Treat Binge Eating

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

President Biden Issues Executive Order on U.S. Supply Chain

Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements